I think the company has no recurring revenue so far and negative cash flows. Further, the compensation from the CEO seems too high compared to the poor performance of the stock, among other things. Both are negative points. The best point is probably the presumed intangibles.
(Usually, I would prefer a net-net which is an operating company with sales).
Biotech net-nets almost always have negative cash flows. I suspect however they perform better than other net-nets, on average, because of the intangible assets you get for free. And despite negative cash flows this one still has a good rank in the net-net list, probably because of low trading volume.
I think the company has no recurring revenue so far and negative cash flows. Further, the compensation from the CEO seems too high compared to the poor performance of the stock, among other things. Both are negative points. The best point is probably the presumed intangibles.
(Usually, I would prefer a net-net which is an operating company with sales).
Biotech net-nets almost always have negative cash flows. I suspect however they perform better than other net-nets, on average, because of the intangible assets you get for free. And despite negative cash flows this one still has a good rank in the net-net list, probably because of low trading volume.